TuHURA Biosciences Inc. (NASDAQ: HURA) announced it has secured a $50 million credit facility from an affiliate of its largest stockholder, K&V Investment One LLC, to fund clinical trials and operations.

The loan agreement allows the immuno-oncology company to draw funds monthly as needed for clinical development and operations. The facility carries a 12% annual interest rate with monthly interest payments and principal due at maturity on April 21, 2031. The loan is secured by company and subsidiary assets.

In connection with the credit facility, TuHURA granted the lender a low to mid-single digit percentage royalty on annual commercial sales of products based on its lead drug candidate IFx-2.0.

The company stated the funding will support development through anticipated Phase 3 results for IFx-2.0 and key efficacy milestones for TBS-2025, extending its cash runway into 2028.

"This agreement allows us to fund operations through anticipated key milestones this year and beyond through anticipated top-line Phase 3 results of our lead IFx-2.0 program," said Dr. James Bianco, president and chief executive officer.

TuHURA is conducting a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company also develops TBS-2025, acquired through its merger with Kineta Inc. on June 30, 2025.

Additional terms of the credit facility and royalty agreement are detailed in the company's Form 8-K filing with the Securities and Exchange Commission.